Latest Pharma and Biotech News
Pharmaceutical
16 May 2025 Danish diabetes and weight loss juggernaut Novo Nordisk is to part ways with its chief executive Lars Fruergaard Jørgensen as the group seeks to reverse its fortunes.
Today's issue
Refine Search
Pharmaceutical
Danish diabetes and weight loss juggernaut Novo Nordisk is to part ways with its chief executive Lars Fruergaard Jørgensen as the group seeks to reverse its fortunes. 16 May 2025
Biotechnology
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma (Nasdaq: INZY) for $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
Biotechnology
Telomir Pharmaceuticals, a US age-reversal science-based biotech, has identified Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections, including those caused by drug-resistant pathogens. 16 May 2025
Pharmaceutical
Chinese pharmaceutical group Jiangsu Hengrui Pharmaceuticals is set to raise up to HK$9.89 billion ($1.27 billion) through a public offering on the Hong Kong Stock Exchange, marking one of the largest listings in the city this year. The move signals renewed momentum in Hong Kong’s capital markets after a prolonged slump. 16 May 2025
Pharmaceutical
US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date for the company’s troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months. 16 May 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Incyte’s Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). 16 May 2025
Biotechnology
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa. 16 May 2025
Pharmaceutical
Chinese AI drug developer METiS Pharmaceuticals is preparing for a Hong Kong initial public offering that could raise up to $200 million, highlighting the ongoing surge of investment in artificial intelligence-powered drug discovery - even as many companies in the sector remain unprofitable. 16 May 2025
Biotechnology
Irish contract research organization ICON has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData. 16 May 2025
Pharmaceutical
Neurocrine Biosciences , the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help children and adults with classic congenital adrenal hyperplasia (CAH) achieve better hormone balance and reduce steroid use. The findings were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando. 16 May 2025
Biotechnology
Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion. The company, based in Boston, plans to use the funds to advance its clinical-stage pipeline and further develop its proprietary AI foundation model for oncology. 16 May 2025
Biotechnology
US clinical-stage biotech Therini Bio yesterday revealed that it raised $39 million in a Series A extension financing, which increased the company’s Series A total to $75 million. 16 May 2025
Biosimilars
The US Food and Drug Administration’s (FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone trend. 16 May 2025
Biotechnology
New York-based Pathos AI, a biotech company applying artificial intelligence (AI) to drug development, has announced a $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. 16 May 2025
Biotechnology
A federal jury in Delaware put US biotech major Amgen on the hook Thursday for at least $271 million in punitive damages arising from an alleged scheme that undercut Regeneron's price for its Praluent (alirocumab). anti-cholesterol drug by bundling Amgen's competing, higher-priced Repatha (evolocumab) with rebates for two expensive, blockbuster medications. 16 May 2025
Pharmaceutical
Shares of Travere Therapeutics fell 15.8% to $21.15 in after-hours trading, as the company revealed that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of Filspari (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS), but with an unexpected glitch. 16 May 2025
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Pharmaceutical
USA-based Inozyme Pharma, a biopharma developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, has a new chief medical officer (CMO). 15 May 2025
Biotechnology
New Jersey, USA-based cancer giant Merck & Co has announced it will unveil a comprehensive slate of new research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 in Chicago. 15 May 2025
Biotechnology
US pharma giant Merck & Co today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers. 15 May 2025
All news
Pharmaceutical
Danish diabetes and weight loss juggernaut Novo Nordisk is to part ways with its chief executive Lars Fruergaard Jørgensen as the group seeks to reverse its fortunes. 16 May 2025
Biotechnology
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma (Nasdaq: INZY) for $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
Biotechnology
Telomir Pharmaceuticals, a US age-reversal science-based biotech, has identified Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections, including those caused by drug-resistant pathogens. 16 May 2025
Pharmaceutical
Chinese pharmaceutical group Jiangsu Hengrui Pharmaceuticals is set to raise up to HK$9.89 billion ($1.27 billion) through a public offering on the Hong Kong Stock Exchange, marking one of the largest listings in the city this year. The move signals renewed momentum in Hong Kong’s capital markets after a prolonged slump. 16 May 2025
Pharmaceutical
US biopharma Biohaven has been told by the US Food and Drug Administration (FDA) that the agency is extending the PDUFA date for the company’s troriluzole new drug application (NDA) for the treatment of spinocerebellar ataxia (SCA) by three months. 16 May 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Incyte’s Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). 16 May 2025
Biotechnology
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa. 16 May 2025
Pharmaceutical
Chinese AI drug developer METiS Pharmaceuticals is preparing for a Hong Kong initial public offering that could raise up to $200 million, highlighting the ongoing surge of investment in artificial intelligence-powered drug discovery - even as many companies in the sector remain unprofitable. 16 May 2025
Biotechnology
Irish contract research organization ICON has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData. 16 May 2025
Pharmaceutical
Neurocrine Biosciences , the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help children and adults with classic congenital adrenal hyperplasia (CAH) achieve better hormone balance and reduce steroid use. The findings were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando. 16 May 2025
Biotechnology
Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion. The company, based in Boston, plans to use the funds to advance its clinical-stage pipeline and further develop its proprietary AI foundation model for oncology. 16 May 2025
Biotechnology
US clinical-stage biotech Therini Bio yesterday revealed that it raised $39 million in a Series A extension financing, which increased the company’s Series A total to $75 million. 16 May 2025
Biosimilars
The US Food and Drug Administration’s (FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone trend. 16 May 2025
Biotechnology
New York-based Pathos AI, a biotech company applying artificial intelligence (AI) to drug development, has announced a $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. 16 May 2025
Biotechnology
A federal jury in Delaware put US biotech major Amgen on the hook Thursday for at least $271 million in punitive damages arising from an alleged scheme that undercut Regeneron's price for its Praluent (alirocumab). anti-cholesterol drug by bundling Amgen's competing, higher-priced Repatha (evolocumab) with rebates for two expensive, blockbuster medications. 16 May 2025
Pharmaceutical
Shares of Travere Therapeutics fell 15.8% to $21.15 in after-hours trading, as the company revealed that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of Filspari (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS), but with an unexpected glitch. 16 May 2025
Pharmaceutical
Swiss pharma giant Novartis will spotlight key data across its oncology portfolio, including Kisqali (ribociclib), Scemblix (asciminib) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which was recently approved for use prior to chemotherapy, at the upcoming 2025 ASCO Annual Meeting. 15 May 2025
Pharmaceutical
USA-based Inozyme Pharma, a biopharma developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, has a new chief medical officer (CMO). 15 May 2025
Biotechnology
New Jersey, USA-based cancer giant Merck & Co has announced it will unveil a comprehensive slate of new research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 in Chicago. 15 May 2025
Biotechnology
US pharma giant Merck & Co today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1 and in all comers. 15 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze